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Abstract
Mammalian host cell invasion by Leishmania is a complex process in which various parasite and host cell components
interact, triggering the activation of signaling cascades in both cells. Little is known regarding PKC biological functions in
Leishmania sp. during parasite-macrophage interaction. PKC-like enzyme was first identified in homogenates and
membrane fraction of L. mexicana stationary promastigotes by immunoblot. PKC-like enzyme activity was then detected in
cell homogenates but also on intact promastigotes showing for the first time the presence of an ecto-PKC dependent on
Ca
2+/phosphatidylserine for activation. This ecto-PKC was activated with phorbol myristate acetate (PMA) and inhibited by
RO-32-0432, a selective PKCabIe bisindolylmaleimide inhibitor. Interestingly, the Leishmania PKC- activity was higher in the
infective stationary than in non-infective logarithmic stage. Then, promastigotes at different stages of time proliferation
curve were used in order to identify the role of PKC-like during macrophage invasion. After attachment to macrophages,
PKC-like is over-expressed in promastigotes at the 6
th culture day but also at the 4
th day of culture corresponding to the
maximal infection capacity. An antibody microarray for MAPK and PKC corroborate the Leishmania PKC-like over-expression
during contact with macrophages. Pretreatment with RO-32-0432 inhibitor reduced the number of infected macrophages
and the parasite burden. These data suggest for the first time a direct link between PKC expression level and infectivity, and
provide evidence that PKC-like plays a critical role in attachment and in the internalization steps involved in the invasion
process.
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Introduction
Leishmaniasis is a public health problem throughout most of the
tropical and subtropical world [1,2] and is a growing concern in
war-torn countries [3–6]. The burden of Leishmaniasis expressed
in disability-adjusted life years (DALYS) is estimated by WHO to
be over 2 million [5]. Like for every parasitic diseases, there is no
vaccines against Leishmaniasis, and chemotherapy is the only
treatment option [7]. Disappointingly few drugs are available in
clinical practice—Pentamidine, Antimonials, Amphotericin B and
Miltefosine— and efficacy is limited due to the toxicity and
increasing multiple drug resistance [8–10]. There is therefore an
urgent need to identify new drug targets.
Leishmania parasites have a complex life cycle that renders the
therapeutic approaches very difficult. Parasites move from the
sandfly midgut up to the mouthparts, then into the human host
where they invade macrophages and live within a phagolyzosoma.
During infection of mammalian host, Leishmania require adaptive
changes to ensure internalization and proliferation into macro-
phages. During internalization some components of the parasite
cell surface such as gp63 and LPG are over-expressed [11–14].
The intermediate steps of signal transduction pathways mediating
these changes are unknown. With the recent publication of the
complete genome sequence of Leishmania major [15], a vast amount
of new information will allow more comprehensive identification
of parasite-specific proteins, among them protein kinases, and their
biological significance.
The recent genomic analysis of Leishmania major shows that they
possess numerous molecules suspected to bind protein kinases (PK)
[16]. By comparing mammalian- and trypanosomatid-PKs, this
analysis clearly indicates that PK phosphorylation is a key
mechanism for the regulation of parasite processes. The
understanding of the structure and function of mammalian PK
is now used to elucidate the function of Leishmania homologues. To
achieve this requires identification of structures and mechanisms
that are either unique to Leishmania or sufficiently different to allow
the identification of specific target molecules. Some of these
proteins and metabolic pathways unique to Leishmania are under
investigation [10]. In mammals, six major groups of eukaryotic
protein kinases (ePK) are defined based on the sequence homology
of their catalytic domain [17]. PK distribution differs between
Leishmania and mammalian cells. First, Leishmania completely lacks
tyrosine kinases (TK) and tyrosine kinase-like (TKL). Second, the
members of AGC family such as protein kinase A, protein kinase
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substantially different from mammalian homologues. They could
be promising drug targets in Leishmania [18]. Protein kinase C
(PKC) represents a family of serine/threonine kinases that consist
of at least 11 isoenzymes organized into three subgroups:
conventional PKCs require diacylglycerol (DAG) and Ca
2+ for
activation, novel PKCs require only DAG for activation, and
atypical PKCs lack responsiveness to DAG and Ca
2+ [19–21]. For
the moment, bioinformatic analyses of Leishmania major protein
kinase genome have not identify a PKC orthologue (PKC-like)
[22]. In the past decade, proteomic analysis of Leishmania
promastigotes using protein kinase inhibitors and activators such
as staurosporine, H7, sphingosine and TPA predicted the presence
of PKC-like activity [23,24,25]. However, because weakly selective
PKC inhibitors were used, direct evidence of this enzyme has often
been contradictory.
Activation of L. amazonensis-PKC modulates the interaction with
host macrophages via secreted acid phosphatase [24]. In a
previous work, we have demonstrated the first evidence of specific
Leishmania PKC-like activity [26]. A recent report confirmed this
PKC-like activity in L. amazonensis and demonstrated that it is
responsible for ion homeostasis maintenance through the modu-
lation of (Na
+,K
+) ATPase activity [27].
The discovery of ecto-protein kinases (ecto-PK) activity has
revealed the regulatory machinery of protein phosphorylation also
operates in the extracellular environment. Numerous reports
demonstrate an ecto-PK activity on the surface of a number of cell
types such as mammalian cells (see for review [28]) and protozoan
parasites such as Entamoeba hystolytica and Toxoplasma gondii [29].
The functional significance of this extracellular phosphorylation
continues to be uncovered, and reports on its implication during
cell proliferation, differentiation and cell interactions have been
cited [28]. We note with interest previous reports of an ecto-PK in
Leishmania. Promastigotes possess PK at the external plasma
membrane surface that is capable phosphorylating endogenous,
membrane and foreign proteins [30]. Only a member of the casein
kinase I (CKI) has been characterized [31]. On the other hand,
extracellular protein phosphorylation in Leishmania increases
during parasite development indicating that protein kinases can
regulate host or parasite cellular processes, and their interactions
[32–34].
In the present study, we identified for the first time an ecto-PKC
in different Leishmania species. We demonstrated, using a
monoclonal antibody recognizing PKCa,bI,bII, its differential
expression during the time promastigote proliferation curve and its
participation in the attachment steps of Leishmania internalization
into macrophages as well as invasion capacity.
Materials and Methods
Cell and parasite cultures
L. mexicana (MHOM/MX/95/NAN1), L. major (MHOM/
SEN/96/NAN2) and L. infantum (MHOM/FR/91/LEM2259)
strains were cultured at 26uC in Schneider’s insect medium
(Sigma Chemical Co., St. Louis, MO, USA), supplemented with
10% fetal bovine serum (FBS, Sigma), penicillin (100 IU/ml)
and streptomycin (100 mg/ml). Promastigotes were harvested at
2
nd,4
th,6
th,a n d8
th growth days for PKC assays. Resident
peritoneal macrophages from male BALB/c mice (R. Janvier-
Le Genest, France) were collected in RPMI 1640 (Sigma)
culture medium supplemented with 10% FBS. Mice were
handled in accordance with existing status of animal treatment
as embodied in the Guiding Principles of Biochemical
Research.
Specificity of anti-PKC antibodies
To date no data are available on the amino acid and/or
nucleotide sequences of Leishmania protein kinase C. The available
information from the L.major genome database has not been
unambiguously identified a PKC ortholog. We therefore used
multiple data sources to infer the specificity of the antibodies used
in this study: Western blots and BLAST searches in the Leishmania
genome for the amino acid sequences (at http://www.genedb.org/
genedb/leish/blast.jsp/) and the sequence alignments (with
http://www.ch. embnet.org/software/LALIGN_form.html and
http://bioinfo. genopole-toulouse.prd.fr/multalin/multalin.html).
We also ‘‘BLASTed’’ the proteins retrieved from the Leishmania
database against all genus kinomes, in order to check for protein
similarities among species.
To choose good candidates for Leishmania PKC-like among the
BLAST hits, we adopted a stringent significance level taken into
account the molecular weight of matched proteins, the scores and
E-values (the cutoff was E,200), because the chance of obtaining
random matches with short amino acid sequences was relatively
large.
Leishmania homogenate and membrane preparations
Promastigotes of L. mexicana were harvested by centrifugation at
2500 g for 10 minutes at 4uC. Cell pellets were suspended and
washed in phosphate buffer saline (PBS) pH 7.2. Subsequent
procedures were performed at 4uC. Packed cells (2.5610
9 cells/
ml) were suspended in 0.02 M Tris-HCl containing 0.25 M
sucrose and 3 mM MgCl2. Cells were homogenized and sonicated
in a Branson homogenizer 250 W. After centrifugation at 1000 g
for 10 minutes, the supernatant was adjusted with 0.1 mM
phenylmethane sulphonyl fluoride (PMSF), 0.02 mg/ml leupeptin
and 0.05 mg/ml aprotinin. The resulting suspension was further
centrifuged at 100000 g for 1 hour and the membrane fraction
(pellet) was separated from the supernatant. Protein concentration
was determined by the Bradford method [35] using bovine serum
albumin (Sigma) as standard. Homogenate and membrane
fraction were directly used for enzyme activity detection or stored
at 280uC until use for immunoblot analysis.
Protein kinase C-like activity
Protein kinase C-like activity was measured by an enzyme-
linked immunosorbent assay, ELISA (Calbiochem, San Diego,
CA). A synthetic PKC pseudosubstrate (RFAARKGSLRQKNV)
and a monoclonal antibody (2B9) that recognizes the phosphor-
ylated form of the peptide were used for PKC activity detection.
Intact promastigotes (2 mg protein/ml), total homogenate (500 mg
protein/ml) and membrane fraction (500 mg protein/ml) were
suspended in a total volume of 100 ml of mixture buffer containing
25 mM Tris-HCl, pH 7.0, 3 mM MgCl2, 0.1 mM ATP, 2 mM
CaCl2,5 0 mg/ml phosphatidylserine, 1 mM EGTA, 0.5 mM
EDTA, 0.1 mM PMSF, 1 mM benzamidine. After 30 min.
incubation at 30uC, biotinylated antibody 2B9 was added to each
well. PKC activity was revealed by a peroxidase-conjugated
streptavidin antibody and by using the ortho-phenyldiamine as
substrate. Plates were read at 492 nm. PKC activity was expressed
in international units (IU/mg) using a PKC control (2000 U/mg,
Promega, USA) as positive control. In some experiments, intact
promastigotes were pretreated with the PKCabIe inhibitor, RO-
32-0432 (Calbiochem) [36] for one hour at concentrations
between 0.0001 and 1 mM. The PKC activator phorbol myristate
acetate (PMA) was used during 15 min at concentrations between
0.035 and 1 mg/ml. Promastigote mobility was monitored after
treatments by light microscopy before measuring the PKC-like
activity.
Leishmania PKC and Infectivity
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Promastigotes were washed in PBS pH 7.2 and centrifuged at
2500 g for 10 minutes. Cell pellets were suspended in 0.02 M Tris-
HCl containing 0.25 M sucrose and 3 mM MgCl2, homogenized
and centrifuged at 14000 g for 15 minutes to eliminate cell debris.
Whole homogenate protein and membrane fractions (40 mg/well)
were boiled in a SDS-PAGE electrophoresis according to
Gallagher method [37], using 10% (w/v) polyacrylamide gels.
Gels were fixed and silver-stained (Sigma). Proteins were also
transferred to 0.45 mm-nitrocellulose membranes (Millipore, Bed-
ford, USA), blocked with PBS-5% milk overnight and incubated
for 2 hr in 0.05% Tween Tris-HCl pH 7.2, containing 1 mg/ml of
mouse monoclonal anti-PKCa,bI,bII (Sigma). After washes,
membranes were incubated with anti-IgG-peroxidase conjugate
(1/3000) (Sigma) for 2 hours. Membrane-bound proteins were
revealed by chemiluminescent detection using luminol as substrate
(Boehringer Mannheim, Germany). In some experiments, pro-
mastigotes were pretreated with 250 ng/ml of PMA during
15 min at room temperature before homogenization.
Leishmania-macrophage internalization assay
Adherent BALB/c peritoneal macrophages were cultured at
37uC in RPMI 1600 medium supplemented with 10% fetal bovine
serum and antibiotics. After 3 washes, L. mexicana promastigotes
(2610
6 cells/ml) were added to 24-wells microplates containing
adherent macrophages (parasite:macrophage ratio, 2:1). After an
18 hours contact, macrophages were washed and stained with
May-Gru ¨nwald-Giemsa. The number of infected macrophages
and the parasite load were calculated observing 100 macrophag-
es/well. Results were expressed as the percentage of inhibition of
these two parameters in comparison to the controls and were
analyzed using the Student’s t-test. In some experiments,
promastigotes were pretreated for 1 hour with the PKC inhibitor
(RO-32-0432) at concentrations between 0.0001 and 1 mM before
the contact with macrophages.
The participation of PKC activity in the attachment step of the
internalization process was studied during L. mexicana proliferation
by incubating promastigotes harvested at 2
nd (middle log-growth
phase), 4
th,6
th, and 8
th growth days with adherent peritoneal
macrophages. Briefly, adherent BALB/c peritoneal macrophages
were cultured at 37uC in RPMI 1600 medium supplemented with
10% fetal bovine serum and antibiotics. After 3 washes,
promastigotes (2610
6 cells/ml) were added to microplates
containing adherent macrophages (parasite:macrophage ratio,
2:1). After 3 hours contact, attached but not internalized
promastigotes were recovered by gently media aspiration. After
3 washes, parasites were counted before lysis. Macrophages
contamination was not observed after light microscopy monitor-
ing. Promastigotes were homogenized in the Western blot buffer
before immunoblot analysis.
Antibody MAPK and PKC microarray assay
L.(L). mexicana promastigotes (4
th culture day) were incubated with
murine BALB/cmacrophages in the same conditions described
above for the investigation of PKC-like activity during the attachment
step. Promastigoteswithout macrophageswere incubated in the same
conditions and used as control. The assay was performed as described
in Panorama Ab Microarray MAPK and PKC pathways kit
according to the manufacturer’s instructions (Sigma). Briefly,
harvested and washed promastigotes were lysed in the Buffer A.
500 mg/ml of protein extract from control and macrophage-
incubated promastigotes were labeled with Cy5 or Cy3, respectively.
Free non-incorporated Cy3 and Cy5 dyes, were separated by
applying the labeled extracts on SigmaSpin post-reaction clean-up
columns. An equal amount of labeled proteins (30 mg) was incubated
on the Panorama Ab microarray slides for 2 hours. After one wash
with 0.01 M PBS pH 7.4, the slides were air-dried before scanning
with the ScanArray Gx (PerkinElmer). Images were generated with
the GenePix software and data from duplicate spotted protein
binding were normalized with respect to anti-actin binding. Also
included in the analysis were the data from two dye-swapped
replicates, in which the samples were reverse color labeled.
Results
Antibody specificity
To choose good candidates for Leishmania PKC-like among the
BLAST hits, we adopted a stringent significance level taken into
account the molecular weight of matched proteins, the scores and E-
values (the cutoff was E,200), because the chance of obtaining
random matches with short amino acid sequences was relatively large.
As summarized in Table 1, the anti-PKCa,bI,bII antibodies
used in this study were raised against polypeptides that yielded
homology hits when ‘‘BLASTed’’ against the Leishmania database.
One homolog was found for putative protein kinase (Q4FYY9).
Five other matches corresponded to hypothetical proteins. Among
these uncharacterized proteins, two were found to be homologous
of mammalian AGC protein kinases (Q4QCI2 and Q4QGQ8).
In summary, we feel confident about the specificity of the
commercially available anti-PKC peptide antibodies, since the
mammalian and Leishmania homologs matched with putative
protein kinases, and the molecular masses of Leishmania and
mammalian homologs are similar.
Leishmania mexicana PKC-like in stationary
promastigotes
L. mexicana promastigotes from the 5
th proliferation day were
analyzed by immunoblot. The presence of a PKC-like enzyme was
detected using an specific antibody for a consensus region of
conventional isotypes of PKC (a, bI, bII). Under native conditions
monoclonal antibody recognizes, in homogenate and membrane
fraction, a band of approximately 78 kDa corresponding to the
molecular mass of the mammalian PKC detected by this antibody.
Densitometric analysis showed that PKC protein level was
significantly higher in the plasma membrane fraction compared
to the homogenate counterpart (Figure 1A).
PKC-like activity was then evaluated by ELISA, using intact
promastigotes, to investigate a putative ecto-PKC activity. Whole
cell homogenates and intact parasites from stationary L. mexicana
promastigotes were compared after incubation with the pseudo-
substrate (RFAARKGSLRQKNV) in the presence of Ca
2+ and
phosphatidylserine for activation. The PKC activity was revealed
using a monoclonal antibody (2B9) that recognizes the phosphor-
ylated form of the peptide. PKC-like activity in homogenates and
on intact promastigotes (ecto-PKC) was 6.3 IU/mg 65.4 and
1.3760.15 IU/mg, respectively. These results confirm that L.
mexicana expresses a Ca
2+/phosphatidylserine-dependent PKC-like
protein also in the external face of plasma membrane.
Intact stationary promastigotes of L. mexicana were then treated
with various concentrations of PMA activator (0.35 to 1 mg/ml)
during 15 minutes and PKC activity was measured at the end of
the experiment. At these concentrations, PMA has not effect on
promastigote mobility after light microscopy observation. As
shown in Figure 1B, PMA treatment caused an increase of
Leishmania ecto-PKC activity that reached a maximum at 250 ng/
ml PMA. The ecto-PKC activity was confirmed by incubating a
selective bisindolylmaleimide PKC inhibitor (RO-32-0432). Pre-
treatment of intact stationary promastigotes of L. mexicana with the
Leishmania PKC and Infectivity
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during 1 h at 26uC reduced the enzyme activity (72%60.2 at
50 nM, p.0.002) in a dose-dependent manner (Figure 1C). At
these concentrations, RO-32-0432 has not effect on promastigote
mobility after light microscopy observation.
This ecto-PKC activity was also detected on intact promasti-
gotes of other Leishmania species such as L. infantum and L. major
(0.6960.04 and 0.6660.06 IU/mg respectively).
Leishmania PKC-like expression during proliferation cycle
In order to discriminate between the logarithmic and stationary
growth phase of cultures, cell proliferation was measured by cell
counting. The logarithmic-growth phase was from the 1
st to the 3
rd
culture day followed by a stationary-growth phase between the 4
th
and the 7
th culture days (Figure 2A).
We were then interested in describing how the PKC-like activity
and level could change during the time proliferation curves of L.
mexicana promastigotes. The ecto-PKC activity was first compared
between non-infective logarithmic (2
nd day) and infective-station-
ary promastigotes (5
th day) of L. mexicana. Baseline levels of ecto-
PKC activity were higher in the stationary (1.3760.15 IU/mg)
than in logarithmic stage of promastigotes (0.8960.2 IU/mg).
Promastigote homogenates harvested at different times in the
proliferation curve, were analyzed by immunoblot. The gels were
loaded with the same amount of protein for each proliferation
stage and immunoblot revealed by the mouse monoclonal anti-
PKCa,bI,bII (Sigma) an anti-beta actin antibody (Sigma) as
control. Results from three different experiments indicated that
the relative levels of PKC depend on promastigote stage of
proliferation. As shown in Figure 2B, levels of PKC were
extremely low at the 2
nd (middle logarithmic-growth phase) and
4
th (early stationary growth phase) days, whereas a marked
increase in enzyme expression was detected only at the 6
th growth
day (middle stationary-growth phase). Interestingly, pretreatment
of promastigotes with 250 ng/ml PMA during 15 min leads to a
substantial increase of PKC protein levels in all proliferative stages.
Implication of PKC-like in the internalization process
Western blot analysis. Participation of PKC-like during
Leishmania attachment step of the internalization process into
Figure 1. Protein kinase C-like detection on stationary promastigotes. (A): Immunoblot detection of PKC-like in subcellular fractions of
stationary promastigotes of L. mexicana. Cell pellets (2.5610
9 cells/ml) were resuspended in 0.02 M Tris-HCl supplemented with 0.25 M sucrose and
3 mM MgCl2. Cells were homogenized and sonicated in a Branson Sonifier 250 W, then resuspended in a buffer containing protease inhibitors and
centrifuged at 100000 g for 1 hour at 4uC. Membrane fraction (pellets) and whole homogenates were directly used for immunoblot detection of PKC
using a mouse monoclonal anti-PKCa,bI,bII antibody. (B): Ecto-PKC-like activity on intact stationary promastigotes of Leishmania. Promastigotes of L.
mexicana were resuspended in 25 mM Tris-HCl, pH 7.0, 3 mM MgCl2, 0.1 mM ATP, 2 mM CaCl2,5 0mg/ml phosphatidylserine, 1 mM EGTA, 0.5 mM
EDTA, 0.1 mM PMSF, 1 mM benzamidine. Phorbol myristate acetate (PMA) was added to cell suspensions in concentration ranging from 0.035 to
1 mg/ml and incubated for 15 min. at 30uC. After washes, promastigotes were incubated for 30 min at 30uC with the biotinylated antibody 2B9. PKC
activity was revealed by a peroxidase-conjugated streptavidin antibody coupled to ortho-phenyldiamine substrate. Plates were read at 492 nm.
Results of three different experiments were expressed in international units (IU/mg) of PKC 6 SD. (C): Ecto-PKC-like inhibition. In some experiments
intact stationary promastigotes were pretreated with the PKCabIe inhibitor RO-32-0432 in concentration ranging from 0.0001 to 1 mM during 1 hour
at 26uC. PKC activity was revealed by incubating with the biotinylated antibody 2B9. Results of three different experiments were represented as the
percentage of PKC activity inhibition 6 SD.
doi:10.1371/journal.pone.0007581.g001
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macrophages infected with L. mexicana promastigotes. In this
model, the capacity of promastigotes to infect macrophage
increased during the time proliferation curve as represented by
the percentage of parasitized macrophages and the number of
intracellular parasites (Figure 3A). Precisely, the significant
capacity of infection was at the 4
th and the 6
th days.
Then we compared promastigote PKC-like expression at
different proliferation stages after 3 hours of contact with
peritoneal BALB/c macrophages to ensure parasite attach-
ment. Immunoblot analysis showed that after attachment to
macrophages, PKC-like is over-expressed in promastigotes at
the 6
th day but also at the 4
th day culture in comparison to the
previous basal PKC-like expression (Fig. 3B). In order to
evaluate whether culture conditions have an effect on PKC-like
expression, the same experiment was developed at different
temperatures (26uCo r3 7 uC) and in the presence or absence of
10% fetal bovine serum (FBS). As shown in Figure 3C, over-
expression of parasite PKC-like after incubation with macro-
phages depended neither on promastigotes heat shocked after
passage in macrophage culture conditions nor on FBS
stimulation, but rather on the cell-cell contact process. In the
same conditions, macrophage-secreted molecules in the culture
supernatant did not have an effect on promastigote PKC-like
expression (Figure 3D).
Leishmania PKC-like involvement in promastigote internalization
into BALB/c macrophages was further studied after treatment
with RO-32-0432 inhibitor for 1 hour. Figure 3E shows that
100 nM RO-32-0432 leads to a significant reduction in the
number of infected macrophages (50%, p,0,004) and parasites
per infected macrophages (72%, p,0,004). These results indicated
that PKC inhibition reduced capacity of Leishmania to internalize
into murine macrophages.
Antibody microarray analysis. V a r i a t i o ni np r o m a s t i g o t e
signaling protein expression after incubation with macrophages
was also analyzed by the Panorama Ab microarray. This
microship composed of 84 different antibodies directed against
kinases and phosphatases of the MAPK and PKC pathways
allowed the detection of specific promastigote protein binding in
spite of the use of antibodies against mammalian proteins. 74
promastigote proteins were specifically recognized on the ship.
Only 4 proteins were considered as significantly differentially
expressed. A increase in the PKC-like expression in
promastigotes after macrophage contact was confirmed by this
method (1.64-fold increase). A stress activating protein kinase
kinase 2 (SKK2, 1.6-fold increase), stress activated protein kinase
3 (SAPK3, 1.33-fold increase) and serine-theronine protein
phosphatase 2Cab (1.23-fold increase) were also associated to
promastigote attachment. Non-proteins were found to be
significantly down-regulated after promastigote contact with
macrophages.
Discussion
During Leishmania sp. life cycle the parasite passes between the
sandfly vector and the mammalian host, oscillating between
replicative forms (promastigote in the sandfly and amastigote
within mammalian macrophage cells) and the cell cycle arrested
metacyclic form, which corresponds to the mammalian-infective
form found within the mouthparts of the sandfly [38,39]. This
later corresponds to the promastigote in stationary-growth phase.
Thus there appears to be an important link between the parasitic
life cycle and its biological development cycle. During these
morphological and metabolic changes, protein kinases are key
regulatory molecules. In fact, changes in phosphoprotein
abundance in Leishmania have been documented throughout
their life cycle [32–34], but their significance for parasite
differentiation and virulence remains unclear to date. The recent
bioinformatics analyses of the L. major genome did not clearly
identify a PKC orthologue [22]. Nonetheless, several lines of
evidence suggest that a Leishmania PKC-like activity is present in
promastigotes and its biological significance is different from the
mammalian counterpart. First, protein phosphorylation increas-
es during Leishmania proliferation, differentiation and interaction
with host cells [32–34]. Second, proteomic analyses of Leishmania
promastigotes by using protein kinase inhibitors and activators
such as staurosporine, H7, sphingosine and TPA predicted the
presence of a PKC-like activity [23]. Third, Leishmania PKC-like
Figure 2. Leishmania PKC-like expression during proliferation.
(A): Time proliferation curve of promastigotes. Parasites were cultured
at 26uC in Schneider’s insect medium supplemented with 10% of fetal
bovine serum and antibiotics. Promastigotes were harvested at the 2
nd,
4
th,6
th, and 8
th growth days and counted on a microscope. (B):
Immunoblot analysis of L. mexicana promastigotes at different stages of
proliferation. 1.10
7 promastigotes (40 mg of protein/well) were tested in
a 10% SDS-PAGE gel electrophoresis. PKC was detected using 1 mg/ml
of an antibody directed to a consensus sequence of mammalian
PKCa,bI,bII.
doi:10.1371/journal.pone.0007581.g002
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interaction with host macrophages [24] and maintenance of
ion homeostasis [27]. Thus, we investigated whether Leishmania
PKC-like could participate during invasion of host macrophages.
Similar to mammalian cells, stationary L. mexicana promastigotes
present a soluble and a membrane-bound form of enzyme [40].
Using a monoclonal antibody recognizing an epitope located
within the amino acid sequence 296–317 at the hinge region of
PKC, immunoblot analysis showed that levels of PKC are more
important in plasma membrane compared to promastigote
homogenates. The putative presence of an ecto-PKC was further
investigated by measuring the phosphorylation by intact promas-
tigotes of a synthetic PKC pseudosubstrate in the presence of Ca
2+
and phosphatidylserine. We showed here the first evidence that an
Figure 3. Implication of Leishmania PKC-like during macrophage internalization. (A): Internalization assay. Promastigotes at the 2
nd,4
th,6
th,
and 8
th growth days were put in contact with adherent murine macrophages in a 2:1 parasite:macrophage ratio and incubated at 37uC, 5% CO2 for
18 hours. Cells were stained with May-Gru ¨nwald-Giemsa and the number of infected macrophages (black column) and the parasite load (gray column)
were calculated observing 100 macrophages/well. Results were expressed as the percentage of inhibition of these two parameters in comparison to
the controls and were analyzed by using Student’s t-test. (B): Expression of parasite PKC during internalization into macrophages. The participation of
PKC activity in the attachment step of internalization process was studied during L. mexicana proliferation by incubating promastigotes harvested at
the 2
nd (middle log-growth phase), 4
th,6
th, and 8
th culture days with adherent peritoneal macrophages. After a 3 hr contact period, promastigotes
were harvested, lyzed and tested for PKC in a SDS-PAGE gel electrophoresis under native conditions using the monoclonal antibody directed to a
consensus sequence of mammalian PKCa,bI,bII. (C): L. mexicana promastigotes at 4th growth day were incubated at 26uCo r3 7 uC in absence or the
presence of 10% FBS. (D): promastigotes were incubated only with the macrophages culture supernatant or with the macrophages during 3 hr
before electrophoresis. (E): Effect of PKC inhibition on L. mexicana promastigote internalization. Stationary promastigotes of L. mexicana (2x10
6 cells/
ml) were pretreated for 1 hr with the selective PKC inhibitor (RO-32-0432) at different concentrations. After washes, promastigotes were added to 24-
wells microplates containing adherent macrophages (parasite:macrophage ratio, 2:1). After 18 hour later macrophages were stained with May-
Gru ¨nwald-Giemsa. The number of infected macrophages (black column) and the parasite load (gray column) were calculated observing 100
macrophages/well. Results were expressed as the percentage of inhibition of these two parameters in comparison to the controls and were analyzed
by Student’s t-test.
doi:10.1371/journal.pone.0007581.g003
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mexicana, L. infantum and L. major promastigotes. This enzyme
activity was dose-dependently inhibited by RO-32-0432, a specific
inhibitor of the bisindolylmaleimide family [41] and increased by
the PMA activator. These results are in contrast to the first
biochemical studies that showed inhibition of substrate phosphor-
ylation by using PKC inhibitors such as sphingosine, currently
questioned because of their poor selectivity [42].
Our results are in accordance with several studies that
demonstrated the presence and activity of membrane externally
PK on Leishmania promastigotes that is capable of phosphorylating
endogenous membrane substrates and foreign proteins [25].
Similar to Trypanosoma cruzi and Trypanosoma brucei PKC, the
activity of PK is Ca
2+/phophatidylserine-dependent [43,44]. In L.
donovani promastigotes, a cyclic-nucleotide-independent protein
kinase has been characterized in the outer surface of the parasite
[23]. However, L. mexicana ecto-PKC detected in this work has
different requirements for activity.
In a second part of our work, we investigated the possible
changes in PKC activity and expression during the time
proliferation curve with a particular attention to the infective
stationary stage. Our results indicated an higher ecto-PKC
activity in infective stationary stage. Other studies have been
reported that Leishmania extracellular protein phosphorylation
increased during parasite develo p m e n t .W ep r o v i d ea l s ot h ef i r s t
evidence of PKC-like level increase during proliferation with a
higher PKC expression at the 6
th day. Expression of PKC can be
induced in all stages of the time proliferation curve after a brief
pretreatment with phorbol esters such as PMA. Protein
phosphorylation by PKC during cell growth was previously
demonstrated for other protozoan parasites such as Trypanosoma
cruzi, Trypanosoma brucei and Entamoeba histolytica [43,44,45].
However, this PKC expression increase was not strictly
correlated with the promastigote infective capacity. Indeed, as
in non-infective logarithmic parasites, PKC expression of
promastigotes harvested in the early infective stationary growth
phase (4
th d a y )w a sv e r yl o ww h e r e a so nt h i sd a y ,t h e
promastigotes are fully infective. It is important to note that
during the attachment to BALB/c macrophages, the first step for
invasion, PKC over-expression was induced in these early
stationary promastigotes (4
th day).
Next we examined the capacity of pre-treated parasites with
RO-32-0432 to invade host cells. We first demonstrated that L.
mexicana PKC modulates the parasite internalization and replica-
tion into BALB/c macrophages. Another research group evi-
denced that pre-treatment with a PKCabc inhibitor (RO31-8220)
reduces both parasite infectivity and growth [46]. In addition, the
pre-treatment of Toxoplasma gondii tachyzoites with 500 nM PMA
enhances parasite infectivity. The TPA pre-treatment of Leishmania
promastigotes before parasite-macrophage interaction enhances
invasion process [24].
The role of ecto-PKC during differentiation from promastigote
to amastigote is a boundary that has never been clearly
established. An increase of protein phosphorylation during the
transition promastigote to axenic amastigotes was the first
observation supporting the idea that protein kinases are presented
into the two stages of Leishmania cell cycle [34,47,48]. For instance
only one ecto-serine/threonine protein kinase have been charac-
terized in Leishmania, the ecto-casein kinase 1, LCK1 [30]. It is
expressed in all the stages of the life cycle, enhanced when switches
to amastigote form. These studies showed not evidence that LCK1
activity was related to PKA or PKC. Activators and inhibitors of
these enzymes had no significant effect on the phosphorylation of
exogenous or endogenous LCK1 substrates.
More recently other laboratories have proposed that the melting
down of the flagellum during promastigote differentiation into
amastigotes, is a process similar to autophagy [49]. This transition
seems to be regulated by coordinated action of protein kinases and
phosphatases. In the light of our results, the ecto-PKC over-
expression during macrophage contact might provide some clues
regarding a potential preadaptation of parasite for survival within
the macrophage.
Using antibodies specific to mammalian mitogen-activated
protein kinases (MAPK) and PKCs in a microarray approach,
we assessed the expression changes of promastigotes proteins
associated with macrophage attachment. The PKC-like over-
expression was confirmed by this method. SKK2 (MKK3, MEK3,
SAPKK2), a stress activating protein kinase kinase 2 was also over-
expressed. Two other proteins, SAPK3 (p38c) and serine-
threonine protein phosphatase 2Cab, showed less expression
changes. These results let to think these MAPKK and MAPK
homologues in Leishmania also participated during the attachment
process.
In Leishmania, MAPK-like kinases have been identified [50–52],
and their significance in parasite flagellar morphology, virulence
and survival has been studied in genetic null mutant studies. We
note with interest a previous work showing the presence of a
conserved MAPK kinase kinase displaying sequence homology
with the mammalian SKKs [50]. This kinase designated
LmxMKK, activates LmxMPK3 during the expression of flagellar
components [53]. It could also be that this MKK homologue
regulates other promastigote functions during the attachment to
host cells.
According to the central residue of the activation lip TXY motif
[54], the TPY and TGY motifs are typical for stress-activated
protein kinases (SAPKs) like p38. In Leishmania genome there are
no typical SAPKs encoded with TPY and TGY motifs. However,
two MAPK, LmxMPK4 and LmxMPK12 carrying a TQY motif
could play a role of SAPKs in L. mexicana [52].
In conclusion, our results demonstrate that PKC-like among an
ecto-PKC is important during Leishmania promastigote develop-
ment through a stage-differential expression. These data suggest
for the first time a direct link between PKC expression level and
infectivity and provide evidence that this PKC-like plays a critical
role in the attachment and in internalization steps of the invasion
process. We hypothesize that, as a consequence of macrophage
attachment, the PKC-like is over-expressed in order to phosphor-
ylate other downstream signaling proteins such as SKK2-like and
SAPK-like proteins. A similar pathway has been characterized in
cancer models demonstrating a direct link between PKCa-
regulated invasion in human carcinoma cells and p38 signaling
[55].
It is important to note that the detection of several specific
binding proteins with the microarray system let to predict other
MAPK and PKCs with conserved domains compared to
mammalian homologues. However, due to limitations associated
to low expression levels in physiological conditions and the
absence of specific antibodies, the real significance of these
proteins remain to be confirmed genetic studies.
With the recent technological advances in the analysis of specific
Leishmania proteins and their functions, new opportunities for drug
development became possible. Hence, there seems to be welcome
change in the attitude of pharmaceutical industry away from a
strictly profit-oriented approach to drug development and towards
a greater pursuit of drugs against nonprofitable diseases [56]. As
with other parasitic diseases, there is no vaccine against
leishmaniasis and chemotherapy involves toxicity and resistance
[10]. The key role of Leishmania-PKC in the invasion process
Leishmania PKC and Infectivity
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new anti-Leishmania drugs.
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